1-(3,5-二氯苯基)-2-羟基乙胺 | 372144-00-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3,5-二氯苯基)-2-羟基乙胺
• 中文别名: 2-氨基-2-(3,5-二氯苯基)乙醇
• 英文名称: 2-Amino-2-(3,5-dichlorophenyl)ethanol
• CAS: 372144-00-8
• 化学式: C₈H₉Cl₂NO
• mdl: MFCD02683179
• 分子量: 206.072
• InChiKey: LRORZXIRKBZZAG-UHFFFAOYSA-N

物化性质

• 沸点：
  275°C (rough estimate)
• 密度：
  1.2408 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2922199090
• 安全说明：
  S26,S37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	1-(3,5-DICHLOROPHENYL)-2-HYDROXYETHYLAMINE Material Safety Data Sheet
Synonym:	None Known.
CAS:	372144-00-8

Section 1 - Chemical Product MSDS Name: 1-(3,5-DICHLOROPHENYL)-2-HYDROXYETHYLAMINE Material Safety Data Sheet
Synonym: None Known.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
372144-00-8	1-(3,5-Dichlorophenyl)-2-hydroxyethyla	ca. 100	unlisted

+++++
Hazard Symbols: XI

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 372144-00-8: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9Cl2NO
Molecular Weight: 206.07

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
None reported.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 372144-00-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(3,5-Dichlorophenyl)-2-hydroxyethylamine - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 372144-00-8: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 372144-00-8 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 372144-00-8 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 3/20/2003 Revision #1 Date: 6/24/2003 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3,5-二氯苯基)-2-羟基乙胺 在 三丁基膦 、 N,N-二异丙基乙胺 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-(2-amino-2-(3,5-dichlorophenyl)ethyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  3-（2-氨基乙基）尿嘧啶衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂的合成及生物学评价

  摘要：

  我们通过在N -3氨基乙基侧链的苯环上引入各种取代基来研究一系列尿嘧啶类似物，并评估其对人促性腺激素释放激素（GnRH）受体的拮抗活性。在邻位或间位具有取代基的类似物表现出有效的体外拮抗活性。具体而言，与未取代的类似物相比，引入2-OMe基团可增强活化T细胞（NFAT）抑制的核因子，最多可提高6倍。我们将化合物12c鉴定为具有中等CYP抑制作用的高效GnRH拮抗剂。化合物12c与已知的拮抗剂Elagolix相比，在cast割的猴子中口服单次给药后，显示出有效且延长的LH抑制作用。我们认为，我们的SAR研究为将GnRH拮抗剂设计为子宫内膜异位症的潜在治疗方法提供了有用的见识。

  DOI：

  10.1016/j.ejmech.2017.12.095
• 作为产物：
  描述：

  3,5-二氯苯甘氨酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 1-(3,5-二氯苯基)-2-羟基乙胺
  参考文献：
  名称：

  3-（2-氨基乙基）尿嘧啶衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂的合成及生物学评价

  摘要：

  我们通过在N -3氨基乙基侧链的苯环上引入各种取代基来研究一系列尿嘧啶类似物，并评估其对人促性腺激素释放激素（GnRH）受体的拮抗活性。在邻位或间位具有取代基的类似物表现出有效的体外拮抗活性。具体而言，与未取代的类似物相比，引入2-OMe基团可增强活化T细胞（NFAT）抑制的核因子，最多可提高6倍。我们将化合物12c鉴定为具有中等CYP抑制作用的高效GnRH拮抗剂。化合物12c与已知的拮抗剂Elagolix相比，在cast割的猴子中口服单次给药后，显示出有效且延长的LH抑制作用。我们认为，我们的SAR研究为将GnRH拮抗剂设计为子宫内膜异位症的潜在治疗方法提供了有用的见识。

  DOI：

  10.1016/j.ejmech.2017.12.095

文献信息

• Nanoscale synthesis and affinity ranking
  作者：Nathan J. Gesmundo、Bérengère Sauvagnat、Patrick J. Curran、Matthew P. Richards、Christine L. Andrews、Peter J. Dandliker、Tim Cernak

  DOI：10.1038/s41586-018-0056-8

  日期：2018.5

  Most drugs are developed through iterative rounds of chemical synthesis and biochemical testing to optimize the affinity of a particular compound for a protein target of therapeutic interest. This process is challenging because candidate molecules must be selected from a chemical space of more than 1060 drug-like possibilities 1 , and a single reaction used to synthesize each molecule has more than 107 plausible permutations of catalysts, ligands, additives and other parameters 2 . The merger of a method for high-throughput chemical synthesis with a biochemical assay would facilitate the exploration of this enormous search space and streamline the hunt for new drugs and chemical probes. Miniaturized high-throughput chemical synthesis3–7 has enabled rapid evaluation of reaction space, but so far the merger of such syntheses with bioassays has been achieved with only low-density reaction arrays, which analyse only a handful of analogues prepared under a single reaction condition8–13. High-density chemical synthesis approaches that have been coupled to bioassays, including on-bead 14 , on-surface 15 , on-DNA 16 and mass-encoding technologies 17 , greatly reduce material requirements, but they require the covalent linkage of substrates to a potentially reactive support, must be performed under high dilution and must operate in a mixture format. These reaction attributes limit the application of transition-metal catalysts, which are easily poisoned by the many functional groups present in a complex mixture, and of transformations for which the kinetics require a high concentration of reactant. Here we couple high-throughput nanomole-scale synthesis with a label-free affinity-selection mass spectrometry bioassay. Each reaction is performed at a 0.1-molar concentration in a discrete well to enable transition-metal catalysis while consuming less than 0.05 milligrams of substrate per reaction. The affinity-selection mass spectrometry bioassay is then used to rank the affinity of the reaction products to target proteins, removing the need for time-intensive reaction purification. This method enables the primary synthesis and testing steps that are critical to the invention of protein inhibitors to be performed rapidly and with minimal consumption of starting materials. A system that combines nanoscale synthesis and affinity ranking enables high-throughput screening of reaction conditions and bioactivity for a given protein target, accelerating the process of drug discovery.

  大多数药物都是通过反复的化学合成和生化测试来开发，以优化特定化合物与治疗感兴趣的蛋白质靶点的亲和力。这一过程颇具挑战性，因为候选分子必须从超过10^60种类药物可能性的化学空间中选出，而用于合成每个分子的单一反应中催化剂、配体、添加剂和其他参数的合理排列组合超过10^7种。将高通量化学合成方法与生化分析方法相结合，将有助于探索这一巨大的搜索空间，并简化新型药物和化学探针的寻找过程。微型化高通量化学合成技术已经能够快速评估反应空间，但迄今为止，这种合成方法与生物分析方法的结合，仅限于低密度反应阵列，即在单一反应条件下仅分析少量类似物。高密度化学合成方法与生物分析方法相结合，包括使用珠子上、表面上、DNA上和质量编码等技术，大大减少了材料需求，但这些方法要求底物与潜在的反应性载体共价连接，必须在高度稀释的情况下进行，并且必须在混合物的形式下运作。这些反应特性限制了过渡金属催化剂的应用，因为过渡金属催化剂很容易受到复杂混合物中存在的多种官能团的毒害，而且对于动力学需要高浓度反应物的反应过程也不适用。本研究将高通量纳摩尔级合成与无标记的亲和选择质谱生物分析相结合，使得每个反应在0.1摩尔浓度的条件下进行，既可能实现过渡金属催化，又使得每个反应消耗的底物不足0.05毫克。然后，使用亲和选择质谱生物分析法对反应产物与靶蛋白的亲和力进行排序，省去了耗时的反应纯化步骤。该方法使得对蛋白质抑制剂发明至关重要的初级合成和测试步骤能够快速完成，且起始材料消耗最小。纳米级合成和亲和力排序相结合的系统可以实现对给定蛋白质靶点的反应条件和生物活性进行高通量筛选，从而加速药物发现过程。
• Highly efficient enantioselective liquid–liquid extraction of 1,2-amino-alcohols using SPINOL based phosphoric acid hosts
  作者：Erik B. Pinxterhuis、Jean-Baptiste Gualtierotti、Hero J. Heeres、Johannes G. de Vries、Ben L. Feringa

  DOI：10.1039/c7sc02783d

  日期：——

  well as the pH and bring to light many previously unsuspected and highly intriguing interactions. Furthermore, utilizing these new insights to our advantage, we developed novel, highly efficient, extraction and resolving protocols which provide remarkable levels of enantioselectivity. It was shown that the extraction is catalytic in host by demonstrating transport in a U-tube and finally it was demonstrated

  以环保和成本有效的方式大规模获得对映纯化合物仍然是化学领域的最大挑战之一。使用对映选择性液-液萃取分离外消旋体具有解决这一挑战的巨大潜力。然而，对该技术背后的化学原理和物理性质的相对较弱的理解阻碍了宿主的发展，该宿主对于将其应用于大规模过程具有足够的分辨能力。在本文中，我们目前使用未经测试的基于SPINOL的磷酸酯宿主家族，以进一步了解ELLE背后的核心原理的方式，对影响氨基醇拆分效率的参数进行了深入研究。我们已经通过诸如溶剂选择，温度以及pH等参数系统地研究了对映异构体的依赖性，并揭示了许多先前未曾想到且高度吸引人的相互作用。此外，利用这些新见解发挥我们的优势，我们开发了新颖，高效的提取和分离方案，可提供出色的对映选择性。结果表明，通过证明在U型管中的运输，萃取在宿主中具有催化作用，最后证明了如何在前所未有的三相拆分系统中利用溶剂依赖性。利用这些新见解发挥我们的优势，我们开发了新颖，高效
• Highly Efficient and Robust Enantioselective Liquid-Liquid Extraction of 1,2-Amino Alcohols utilizing VAPOL- and VANOL-based Phosphoric Acid Hosts
  作者：Erik B. Pinxterhuis、Jean-Baptiste Gualtierotti、Sander J. Wezenberg、Johannes G. de Vries、Ben L. Feringa

  DOI：10.1002/cssc.201701896

  日期：2018.1.10

  previously untested class of hosts, VAPOL and VANOL derived phosphoric acids, has been studied in depth for the efficient enantioselective liquid–liquid extraction of 1,2‐amino alcohols. A systematic investigation of extraction parameters was conducted, revealing many key interactions and DFT calculations illustrate the binding modes for the 1:1 complexes that are involved in chiral recognition. The resulting

  以经济高效且环保的方式大规模生产对映纯化合物仍然是现代化学的主要挑战之一。通过对映选择性液-液萃取来拆分外消旋体是一种合适的解决方案，但由于缺乏高效，强健的手性宿主来介导该过程，因此在很大程度上仍未得到充分利用。宿主缺乏的部分原因是对这些过程背后的基本原理的了解不足，从而阻碍了更高效选择器的设计。对于有效的对映选择性液-液萃取1,2-氨基醇，已经对VAPOL和VANOL衍生的磷酸一类未经测试的宿主进行了深入研究。对提取参数进行了系统的研究，揭示了许多关键的相互作用，DFT计算说明了手性识别所涉及的1：1配合物的结合模式。由此产生的，现在经过优化的过程非常健壮且易于实施。如U型管实验所示，它们还易于扩展。
• 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS
  申请人：Akritopoulou-Zanze Irini

  公开号：US20090203690A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R 1 , R 2 , R 3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

  本发明涉及式（I）的化合物或药物可接受的盐，其中A，R1，R2，R3和m在说明书中定义。本发明还涉及制备所述化合物的方法，以及含有所述化合物的组合物，该组合物对抑制激酶如糖原合成酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），Cdc7，AKT，PAK4，PLK，CK2，KDR，MK2，JNK1，极光激酶，pim 1和nek 2有用。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。